1-[5-(2-羟基乙基)硫代]-4-硝基-2-噻吩]乙基-1-酮 | 5578-67-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-[5-(2-羟基乙基)硫代]-4-硝基-2-噻吩]乙基-1-酮
• 英文名称: 3,3'-dicarboxy-2,2'-dihydroxydiphenylmethane
• 英文别名: 2,2'-dihydroxy-3,3'-methanediyl-di-benzoic acid；2,2'-Dihydroxy-3,3'-methandiyl-di-benzoesaeure；Bis-(3-carboxy-2-hydroxy-phenyl)-methan；Methylen-disalicylsaeure；3,3'-Methylenedisalicylic acid；3-[(3-carboxy-2-hydroxyphenyl)methyl]-2-hydroxybenzoic acid
• CAS: 5578-67-6
• 化学式: C₁₅H₁₂O₆
• 分子量: 288.257
• InChiKey: RWXFMUMBJLQGDZ-UHFFFAOYSA-N

物化性质

• 物理描述：
  DryPowder

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  115
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1-[5-(2-羟基乙基)硫代]-4-硝基-2-噻吩]乙基-1-酮 在 四氢呋喃 、 lithium aluminium tetrahydride 作用下， 生成 2,2'-dihydroxy-3,3'-methanediyl-di-benzyl alcohol
  参考文献：
  名称：

  Carpenter; Hunter, Journal of Applied Chemistry, 1953, vol. 3, p. 486,493

  摘要：

  DOI：
• 作为产物：
  描述：

  5-溴水杨酸 在 palladium on activated charcoal 氢氧化钾 、 氢气 作用下， 以 甲醇 为溶剂， 25.0 ℃ 、101.33 kPa 条件下， 反应 36.0h， 生成 1-[5-(2-羟基乙基)硫代]-4-硝基-2-噻吩]乙基-1-酮
  参考文献：
  名称：

  Synthesis and anti-HIV activities of low molecular weight aurintricarboxylic acid fragments and related compounds

  摘要：

  Several compounds corresponding to fragments of the schematic representation of the polymeric structure of aurintricarboxylic acid (ATA) have been prepared and tested for prevention of the cytopathic effect of HIV-1 and HIV-2 in MT-4 cell culture and HIV-1 in CEM cell culture. Both the triphenylcarbinol 3 as well as the triphenylmethane 5 were found to afford protection against the cytopathogenicity of HIV-2 in MT-4 cells and HIV-1 in CEM cells, but they were inactive against HIV-1 in MT-4 cells. Both substances were also found to inhibit syncytium formation when MOLT-4 cells were cocultured with HIV-2-infected HUT-78 cells, but were inactive in this assay against HIV-1-infected cells. When observed, the activity is generally moderate in degree of protection and requires concentrations in the 10(-4) molar range. In contrast to ATA, both of these substances were inactive when tested for prevention of the binding of the OKT4A monoclonal antibody to the CD4 receptor and also for inhibition of HIV-1 reverse transcriptase. These substances therefore appear act by a mechanism that is distinct from that of polymeric ATA. Several active and inactive structural analogues of 3 and 5 were also synthesized. The anti-HIV activity in this series seems to depend on the presence of anionic carboxylate groups, since the methyl esters 4, 6, and 12 were uniformly inactive. The diphenylmethanes 8, 14, 18, and 19 also reproducibly inhibited the cytopathic effect of HIV-1 in CEM cell culture.

  DOI：

  10.1021/jm00105a053

文献信息

• [EN] ANTIBODY DRUG CONJUGATES<br/>[FR] CONJUGUÉS ANTICORPS-MÉDICAMENT
  申请人：TAKEDA PHARMACEUTICALS CO

  公开号：WO2020229982A1

  公开（公告）日：2020-11-19

  The present disclosure provides antibody drug conjugates comprising STING modulators. Also provided are compositions comprising the antibody drug conjugates. The compounds and compositions are useful for stimulating an immune response in a subject in need thereof. Formula (I):

  本公开提供包含STING调节剂的抗体药物结合物。还提供了包含该抗体药物结合物的组合物。这些化合物和组合物对于刺激需要免疫反应的受试者是有用的。公式（I）:
• [EN] ADMINISTRATION OF UBIQUITIN-ACTIVATING ENZYME INHIBITOR AND RADIATION<br/>[FR] CO-ADMINISTRATION D'UN INHIBITEUR D'ENZYME ACTIVANT L'UBIQUITINE ET DE RAYONS
  申请人：MILLENNIUM PHARM INC

  公开号：WO2016069393A1

  公开（公告）日：2016-05-06

  Disclosed are methods for the treatment of cancer in patients in need of such treatment. The methods comprise administering to such a patient an ubiquitin-activating enzyme (UAE) inhibitor such as ((1R,2R,3S,4R)-2,3-dihydroxy-4-(2-(3-(trifluoromethylthio) phenyl)pyrazolo[1,5-a]pyrimidin-7-ylamino)cyclopentyl)methyl sulfamate (Compound 1) or a pharmaceutically acceptable salt in combination with radiation. Also disclosed are medicaments for use in the treatment of cancer.

  揭示了治疗癌症的方法，适用于需要此类治疗的患者。这些方法包括向这样的患者施用泛素激活酶（UAE）抑制剂，如((1R,2R,3S,4R)-2,3-二羟基-4-(2-(3-(三氟甲基硫基)苯基)吡唑并[1,5-a]嘧啶-7-基氨基)环戊基)甲基磺酸酯（化合物1）或药学上可接受的盐与放射线结合使用。还披露了用于癌症治疗的药物。
• [EN] NEODEGRADER CONJUGATES<br/>[FR] CONJUGUÉS DE TYPE NEODEGRADER
  申请人：ORUM THERAPEUTICS INC

  公开号：WO2021198965A1

  公开（公告）日：2021-10-07

  The present disclosure provides neoDegraders and neoDegraders conjugated to binding moieties. Also provided are compositions comprising the conjugates. The compounds and compositions are useful for treating a disease or condition, e.g., cancer, in a subject in need thereof.

  本公开提供了与结合基团结合的neoDegraders和neoDegraders。还提供了包含这些结合物的组合物。这些化合物和组合物对于治疗患有疾病或症状的受试者（例如癌症）是有用的。
• HYDROXYTRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF
  申请人：Japan Tobacco Inc.

  公开号：US20170057943A1

  公开（公告）日：2017-03-02

  The present invention provides a compound having an mPGES-1 inhibitory activity and useful for the prophylaxis or treatment of pain, rheumatism, osteoarthritis, fever, Alzheimer's disease, multiple sclerosis, arteriosclerosis, glaucoma, ocular hypertension, ischemic retinal disease, systemic scleroderma and/or cancer including colorectal cancer. The present invention relates to a compound of formula [I-a], [I-b] or [I-c] or a pharmaceutically acceptable salt thereof: wherein each symbol is as defined in the specification.

  本发明提供了一种具有mPGES-1抑制活性的化合物，用于预防或治疗疼痛、风湿病、骨关节炎、发热、阿尔茨海默病、多发性硬化症、动脉硬化、青光眼、眼压增高、缺血性视网膜疾病、全身性硬皮病和/或包括结直肠癌在内的癌症。本发明涉及具有化学式[I-a]、[I-b]或[I-c]的化合物或其药学上可接受的盐：其中每个符号如规范中所定义。
• COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS
  申请人：Lantheus Medical Imaging, Inc.

  公开号：US20150196672A1

  公开（公告）日：2015-07-16

  The present invention provides compounds with imaging moieties for imaging a subject. The present invention also relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, a composition or plurality of imaging agents is enriched in 18 F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.

  本发明提供了具有成像基团的化合物，用于对受试者进行成像。本发明还涉及用于合成和使用成像试剂或其前体的系统、组合物和方法。成像试剂前体可以使用本文所述的方法转化为成像试剂。在某些情况下，组合物或多种成像试剂富集于 18 F。在某些情况下，成像试剂可用于成像受试者的感兴趣区域，包括但不限于心脏、心血管系统、心脏血管、大脑和其他器官。